Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Zhu D, Zhao J, Cai H, Chu X, Xiu S, Song C, Cheng Z, Cao H, Jiang H, Zhang L, Wang H, Shi B and 10 more

Show all authors

Li Y, Liu M, Feng B, Xue F, Deng H, Li H, Li L, Li Y, Ma Q, Qian L

Nature17 Dec 2025Cited by 11 (Europe PMC)

PMID41407859DOI10.1038/s41586-025-10026-wPepBankPUB-41407859

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 4 mg lowered HbA1c more than placebo at week 24 (treatment difference -1.43%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 4 mg lowered HbA1c more than placebo.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change at week 24 (4 mg)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.57%
mazdutide 4 mg
HbA1c change
−0.14%
placebo
Treatment difference in HbA1c
−1.43%
mazdutide 4 mg vs placebo
Source sentences
Summary
At week 24, mazdutide significantly reduced HbA_1c versus placebo (primary endpoint): -1.57% with mazdutide 4 mg and -2.15% with mazdutide 6 mg, versus -0.14% with placebo, with treatment differences of -1.43% and -2.02% (both P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785901
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 6 mg lowered HbA1c more than placebo at week 24 (treatment difference -2.02%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 6 mg lowered HbA1c more than placebo.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change at week 24 (6 mg)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 mg · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−2.15%
mazdutide 6 mg
HbA1c change
−0.14%
placebo
Treatment difference in HbA1c
−2.02%
mazdutide 6 mg vs placebo
Source sentences
Summary
At week 24, mazdutide significantly reduced HbA_1c versus placebo (primary endpoint): -1.57% with mazdutide 4 mg and -2.15% with mazdutide 6 mg, versus -0.14% with placebo, with treatment differences of -1.43% and -2.02% (both P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785902
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo reached HbA1c below 7.0% at week 24 (all P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo reached an HbA1c below 7.0%.
Peptide
Mazdutide
Outcome
IncreaseProportion reaching HbA1c below 7.0% at week 24
Study
n = 320
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg and 6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, more participants with mazdutide achieved HbA_1c 1c < 7.0% and weight loss ≥ 5%) versus placebo (P = 0.0006 for 4 mg; P < 0.0001 for 6 mg) at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785905
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide than on placebo lost at least 5% of body weight at week 24 (all P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide than on placebo lost at least 5% of body weight.
Peptide
Mazdutide
Outcome
IncreaseProportion with weight loss of at least 5% at week 24
Study
n = 320
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg and 6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, more participants with mazdutide achieved HbA_1c 1c < 7.0% and weight loss ≥ 5%) versus placebo (P = 0.0006 for 4 mg; P < 0.0001 for 6 mg) at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785906
05HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, diarrhoea was among the most common adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, diarrhoea was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedDiarrhoea
Study
n = 320
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events-diarrhoea, decreased appetite and nausea-were consistent with GLP-1R agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785909
06HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, decreased appetite was among the most common adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, decreased appetite was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedDecreased appetite
Study
n = 320
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
4 mg and 6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events-diarrhoea, decreased appetite and nausea-were consistent with GLP-1R agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785910
07HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes, nausea was among the most common adverse events with mazdutide.
In plain wordsIn Chinese adults with type 2 diabetes, nausea was one of the most common side effects of mazdutide.
Peptide
Mazdutide
Outcome
Direction not reportedNausea
Study
n = 320
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
4 mg and 6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events-diarrhoea, decreased appetite and nausea-were consistent with GLP-1R agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785911
08HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 4 mg reduced body weight more than placebo at week 24 (-5.61% versus -1.26%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 4 mg lowered body weight more than placebo.
Peptide
Mazdutide
Outcome
DecreaseBody weight change at week 24 (4 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
4 mg · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Body weight change
−5.61%
mazdutide 4 mg
Body weight change
−1.26%
placebo
Source sentences
Summary
Weight loss from baseline at week 24 occurred with -5.61% (4 mg) and -7.81% (6 mg) versus -1.26% (placebo) (both P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785903
09HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, mazdutide 6 mg reduced body weight more than placebo at week 24 (-7.81% versus -1.26%, P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, mazdutide 6 mg lowered body weight more than placebo.
Peptide
Mazdutide
Outcome
DecreaseBody weight change at week 24 (6 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
6 mg · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Body weight change
−7.81%
mazdutide 6 mg
Body weight change
−1.26%
placebo
Source sentences
Summary
Weight loss from baseline at week 24 occurred with -5.61% (4 mg) and -7.81% (6 mg) versus -1.26% (placebo) (both P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785904
10HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide 4 mg than on placebo met the composite of HbA1c below 7.0% and weight loss of at least 5% (P = 0.0006).
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide 4 mg than on placebo reached both the HbA1c goal and 5% weight loss.
Peptide
Mazdutide
Outcome
IncreaseComposite endpoint HbA1c below 7.0% and weight loss of at least 5% (4 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
4 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, more participants with mazdutide achieved HbA_1c 1c < 7.0% and weight loss ≥ 5%) versus placebo (P = 0.0006 for 4 mg; P < 0.0001 for 6 mg) at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785907
11HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes, more participants on mazdutide 6 mg than on placebo met the composite of HbA1c below 7.0% and weight loss of at least 5% (P < 0.0001).
In plain wordsIn Chinese adults with type 2 diabetes, more people on mazdutide 6 mg than on placebo reached both the HbA1c goal and 5% weight loss.
Peptide
Mazdutide
Outcome
IncreaseComposite endpoint HbA1c below 7.0% and weight loss of at least 5% (6 mg)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
6 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Furthermore, more participants with mazdutide achieved HbA_1c 1c < 7.0% and weight loss ≥ 5%) versus placebo (P = 0.0006 for 4 mg; P < 0.0001 for 6 mg) at week 24.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3 trial, 320 participants (mean glycated haemoglobin A1c (HbA_1c) of 8.24%, body mass index of 28.2 kg m^-2 and diabetes duration of 1.9 years) were randomized 1:1:1 to receive weekly subcutaneous injections of mazdutide (4 mg or 6 mg) or placebo for 24 weeks, follo…
Report a problemFND-4140785908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 4NCT07654062

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Shandong Provincial Hospitaln = 150est. Jul 2026 to est. Jul 2029

Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance (Prediabetes)

Trial page ClinicalTrials.govUpdated 17 Jun 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.